ZoAnn E Dreyer Selected Research

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)

5/2023	Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.
1/2022	Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial.
5/2021	Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
1/2021	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
1/2019	The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group.
1/2019	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
10/2018	Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients.
4/2017	Comparison of height and weight after 12 vs. 18 Gy cranial radiation therapy in pediatric acute lymphoblastic leukemia (ALL) patients.
12/2016	Deliberate liver transplantation for fulminant liver failure with acute lymphoblastic leukemia.
2/2016	Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

ZoAnn E Dreyer Research Topics

Disease

18	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 05/2023 - 05/2007
4	Leukemia 01/2021 - 05/2007
2	Hypersensitivity (Allergy) 02/2016 - 07/2014
2	Neoplasms (Cancer) 01/2011 - 10/2003
1	Residual Neoplasm 05/2023
1	Medulloblastoma 01/2021
1	Scoliosis 01/2021
1	Inflammation (Inflammations) 12/2020
1	Hodgkin Disease (Hodgkin's Disease) 12/2020
1	Neurologic Manifestations (Neurological Manifestations) 10/2018
1	Acute Liver Failure (Fulminant Hepatic Failure) 12/2016
1	Infections 03/2015
1	Hypertension (High Blood Pressure) 03/2014
1	Cardiovascular Diseases (Cardiovascular Disease) 03/2014
1	Cardiomyopathies (Cardiomyopathy) 03/2014
1	Brain Neoplasms (Brain Tumor) 10/2003

Drug/Important Bio-Agent (IBA)

3	Methotrexate (Mexate)FDA LinkGeneric 01/2019 - 05/2007
2	lestaurtinibIBA 05/2021 - 01/2021
2	Asparaginase (Elspar)FDA Link 02/2016 - 07/2014
2	AnthracyclinesIBA 03/2014 - 10/2003
1	MethyltransferasesIBA 05/2023
1	Lysine (L-Lysine)FDA Link 05/2023
1	CytokinesIBA 12/2020
1	ProteomeIBA 12/2020
1	ChemokinesIBA 12/2020
1	Ribavirin (Virazole)FDA LinkGeneric 01/2019
1	Eukaryotic Initiation Factor-4EIBA 01/2019
1	pegaspargase (Oncaspar)FDA Link 01/2016
1	Hyaluronan SynthasesIBA 03/2014
1	obatoclaxIBA 04/2013
1	Proteins (Proteins, Gene)FDA Link 04/2013
1	Biomarkers (Surrogate Marker)IBA 04/2012
1	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 04/2012
1	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 10/2003
1	Daunorubicin (Cerubidine)FDA LinkGeneric 10/2003

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 01/2022 - 01/2011
6	Therapeutics 12/2020 - 01/2011
2	Radiotherapy 01/2021 - 04/2017
1	Craniospinal Irradiation 01/2021
1	Liver Transplantation 12/2016
1	Hematopoietic Stem Cell Transplantation 01/2011